Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) generates frequent news as a commercial-stage biopharmaceutical company focused on C3 complement science. Its updates often center on the performance and expansion of its approved C3-targeting medicines, SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration and EMPAVELI/Aspaveli for complement-mediated rare diseases such as C3 glomerulopathy (C3G), primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria (PNH).
Investors following APLS news can expect regular disclosures on commercial execution, including U.S. net product revenues, patient start forms, market share in GA, and payer coverage trends in C3G and primary IC-MPGN. Apellis also issues news on long-term clinical data, such as five-year GALE extension results for SYFOVRE and one-year VALIANT data for EMPAVELI, which highlight durability of treatment effect and safety profiles.
Another major category of Apellis news involves clinical and regulatory milestones. Releases cover Phase 2 and Phase 3 trial progress, pivotal trial initiations in new nephrology indications like focal segmental glomerulosclerosis and delayed graft function, regulatory approvals, and opinion timelines from agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. The company also announces publication of key data in peer-reviewed journals, including The New England Journal of Medicine.
Corporate and financial communications are a further news stream, including quarterly financial results, cash and cash equivalents updates, royalty and collaboration agreements with partners such as Sobi, and participation in major healthcare and investor conferences. For readers tracking APLS, this news page provides a centralized view of Apellis’ commercial performance, pipeline evolution, regulatory events, and strategic transactions related to its complement-based therapies.
Apellis (Nasdaq: APLS) announced that Mikael Dolsten, M.D., Ph.D., joined its board of directors effective March 1, 2026. Dr. Dolsten served more than 16 years as chief scientific officer and president, worldwide R&D and medical, at Pfizer and presided over regulatory approval of more than 36 medicines and vaccines.
He brings extensive pharma R&D leadership, previous roles at multiple major firms, current public and private board service, and advisor roles with investment groups to support Apellis’ complement-focused pipeline.
Apellis (Nasdaq: APLS) reported full-year 2025 net product revenues of $689 million—SYFOVRE $587 million and EMPAVELI $102 million. Cash and cash equivalents were $466.2 million at year-end. The company recorded a one-time $275 million upfront from Sobi and expects SYFOVRE prefilled syringe submission in H1 2026.
Apellis reported full-year net income of $22.4 million and faces a larger Q4 net loss of $58.9 million; EMPAVELI launches and pivotal kidney trials are underway.
Apellis (Nasdaq: APLS) will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
The live webcast will be posted on the company’s Events and Presentations investor page and a replay will be available for approximately 30 days following the event.
Apellis (Nasdaq: APLS) will present eight oral abstracts at the 49th Macula Society Annual Meeting, Feb 25-28, 2026 in San Diego, including five-year results from the GALE extension (n=792) showing impact of early, continuous SYFOVRE (pegcetacoplan) treatment on geographic atrophy progression.
Presentations cover GALE, OAKS & DERBY analyses, AI imaging, real-world treatment patterns, and safety/visual function findings.
Apellis Pharmaceuticals (Nasdaq: APLS) will host a conference call and webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results.
Investors can preregister to access the live call by phone, view a live audio webcast and slides via the company’s Investors and Media Events and Presentations page, and access a replay for 30 days.
Apellis (NASDAQ: APLS) reported preliminary full‑year 2025 U.S. net product revenues of $689 million and year‑end cash and cash equivalents of approximately $466 million. SYFOVRE delivered ~102,000 doses in 2025, held ~60% GA market share, and total injection demand grew 17% YoY. EMPAVELI posted preliminary 2025 U.S. revenues of $102 million with 267 cumulative patient starts by Dec 31, 2025 and >5% U.S. market penetration in C3G/IC‑MPGN. Company plans a SYFOVRE prefilled syringe submission in 1H 2026, initiated pivotal EMPAVELI trials in FSGS and DGF, and expects current cash plus revenues to fund operations to profitability.
Apellis Pharmaceuticals (NASDAQ:APLS) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. The company said a live webcast of the presentation will be posted on the Events and Presentations page in its Investors and Media section. A replay will be available for approximately 90 days after the event.
Apellis (Nasdaq: APLS) announced that NEJM published positive Phase 3 VALIANT results for EMPAVELI (pegcetacoplan) in C3 glomerulopathy (C3G) and primary IC-MPGN at Week 26.
Key results: 68% proteinuria reduction versus placebo (p<0.0001); eGFR stabilization +6.3 mL/min/1.73 m2 versus placebo (nominal p=0.03); and 71% of treated patients achieved zero C3 staining. EMPAVELI showed a favorable safety profile consistent with prior experience and was FDA-approved July 28, 2025.
Apellis Pharmaceuticals (Nasdaq: APLS) announced management will participate in webcast fireside chats at two investor conferences: Citi 2025 Global Healthcare Conference on December 2, 2025 at 2:30 p.m. ET and Evercore 8th Annual Healthcare Conference on December 3, 2025 at 2:10 p.m. ET.
Live webcasts will be posted on the company’s Investors and Media > Events and Presentations webpage. A replay will be available for approximately 30 days after each event.
Apellis (Nasdaq: APLS) reported five-year post hoc GALE data showing continuous treatment with SYFOVRE (pegcetacoplan) delayed geographic atrophy (GA) lesion growth by approximately 1.5 years versus sham/projected sham in patients with nonsubfoveal GA. Both monthly and every-other-month dosing regimens showed similar delay. The safety profile through five years remained consistent with prior reports. Detailed results will be presented at a future medical meeting.